RxDoctor Payments Data

Gregory Nelson

Ophthalmology · Arlington Heights, ILNPI 1043221351

Payments from drug & device makers

$4,966in general payments, 2019–2025

Across 202 payments — averaging $24.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$1K
  • Aerie Pharmaceuticals, Inc.$431
  • Bausch & Lomb Americas Inc.$328
  • Oyster Point Pharma, Inc.$192
  • Rxsight Inc$164
  • plus $760 from 14 others

What the payments were for

  • Food & beverage$4,92199%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,966 in reported general payments places this provider in the 75th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$845,655
Medicare patients
2,180
Services billed
6,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost304$171,943
RocklatanNetarsudil Mesylat/Latanoprost117$71,854
RestasisCyclosporine46$57,997
CombiganBrimonidine Tartrate/Timolol123$53,133
Latanoprost1,835$26,537
Travoprost110$22,409
SimbrinzaBrinzolamide/Brimonidine Tart87$22,023
VyzultaLatanoprostene Bunod31$21,669
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol77$18,096
RhopressaNetarsudil Mesylate23$14,531
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat762$14,172
ZioptanTafluprost/Pf26$13,581
Alphagan PBrimonidine Tartrate18$9,448
Brimonidine Tartrate337$9,348
AzoptBrinzolamide12$8,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,940$292,521491 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$431$86,385140 claims
AlconSimbrinza, Azopt$1,151$30,27299 claims
Bausch & Lomb Americas Inc.Vyzulta$328$21,66931 claims
NovartisTravatan Z$162$6,33011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →